Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478643 | 0.92 | LMNA (0.47) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL4492762 | 0.91 | EGLN1 (0.47) | SMN1; SMN2LMNAHTTALDH1A1KMT2A | |
| SCHEMBL4477132 | 0.88 | LMNA (0.50) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL4487053 | 0.84 | LMNA (0.50) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL6032053 | 0.83 | LMNA (0.49) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL4502946 | 0.81 | AKR1B1 (0.43) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL4502970 | 0.80 | EGLN1 (0.45) | SMN1; SMN2LMNAL3MBTL1HTTALDH1A1 | |
| SCHEMBL4487206 | 0.80 | MEN1 (0.49) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL4489537 | 0.79 | LMNA (0.45) | SMN1; SMN2LMNAL3MBTL1NCOA3HTT | |
| SCHEMBL2728496 | 0.79 | EGLN1 (0.44) | SMN1; SMN2LMNAL3MBTL1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598264-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070179196-A1 | Hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-08-02 | — | — | US | disclosed |
| EP-1725556-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005087768-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087767-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179196-A1 | Hiv integrase inhibitors | REV1, TYMP, POLR2H | SMN1; SMN2 4492/4885LMNA 4273/4885L3MBTL1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.